Weight-loss medicines: what good clinical support looks like

Medicines such as tirzepatide and semaglutide act on hormone pathways involved in appetite, fullness and digestion. Orlistat works differently by reducing the absorption of some dietary fat. The appropriate option depends on eligibility, health conditions, other medicines and personal goals.

NICE guidance places medicine alongside a reduced-calorie diet and increased physical activity. That does not mean relying on willpower: useful care includes realistic nutrition advice, activity that fits your ability and support with eating patterns and setbacks.

A prescriber should confirm height and weight, medical history, current medicines, pregnancy plans and relevant conditions. They should explain expected benefits, common side effects, serious warning signs, dose escalation and what happens if treatment is not helping.

Nausea, diarrhoea, constipation and abdominal discomfort can occur with injectable medicines. Severe persistent abdominal pain, repeated vomiting, dehydration or symptoms of an allergic reaction need prompt medical advice. The patient leaflet contains the complete safety information for the specific product.

Good follow-up tracks more than kilograms. Blood pressure, metabolic health, nutrition, strength, side effects and emotional wellbeing may all matter. Dose changes should be clinical decisions, not a race to the highest dose.

Weight may return after stopping treatment, so the conversation should include maintenance and what support remains available. If you use oral contraception, tell the prescriber: some weight-management medicines can affect absorption around starting treatment or dose increases and may require additional contraception.